- Conditions
- Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Dedifferentiated Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Mixed Cell Adenocarcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Endometrial Undifferentiated Carcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
- Interventions
- Carboplatin, Computed Tomography, Paclitaxel, Pembrolizumab, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 813 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 370
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 272 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Anal Cancer
- Interventions
- cisplatin, fluorouracil, mitomycin C, radiation therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 682 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2016
- U.S. locations
- 484
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 331 more
- Conditions
- Leukemia
- Interventions
- DNA analysis, Southern blotting, cytogenetic analysis, polymerase chain reaction
- Genetic
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- Not listed
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 161
- States / cities
- San Diego, California • San Francisco, California • Lewes, Delaware + 89 more
- Conditions
- Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v7, Stage IIB Colon Cancer AJCC v7, Stage IIC Colon Cancer AJCC v7
- Interventions
- Bevacizumab, Fluorouracil, Leucovorin, Oxaliplatin
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 2,431 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2027
- U.S. locations
- 911
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 578 more
- Conditions
- Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
- Interventions
- Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Lenalidomide, Rituximab
- Drug · Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 418 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2023
- U.S. locations
- 355
- States / cities
- Scottsdale, Arizona • Arroyo Grande, California • Burbank, California + 238 more
- Conditions
- Ulcerative Colitis (UC)
- Interventions
- Not listed
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 8,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2028
- U.S. locations
- 169
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 131 more
- Conditions
- Recurrent Mantle Cell Lymphoma
- Interventions
- Bortezomib, Laboratory Biomarker Analysis, Lenalidomide
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 82
- States / cities
- Anaheim, California • Baldwin Park, California • Bellflower, California + 62 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- alemtuzumab
- Biological
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 69
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 60 more
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL, Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA, Alkylating Agent-Related Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome, Untreated Adult Acute Myeloid Leukemia
- Interventions
- Azacitidine, Entinostat, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 234
- States / cities
- Scottsdale, Arizona • Burbank, California • Los Angeles, California + 146 more
- Conditions
- HIV Infections, Pregnancy Complications, Infectious
- Interventions
- Adherence assessment
- Behavioral
- Lead sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
- Network
- Eligibility
- 14 Years and older · Female only
- Enrollment
- 3,090 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2013
- U.S. locations
- 75
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more
- Conditions
- Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Mucosal Melanoma
- Interventions
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Therapeutic Conventional Surgery
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 817
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 512 more
- Conditions
- Latent Tuberculosis
- Interventions
- Rifapentine daily for 6 weeks, Rifapentine and Isoniazid weekly for 12 weeks, Rifampin and Isoniazid daily for 12 weeks, Rifampin daily for 16 weeks
- Drug
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- Not listed
- Enrollment
- 3,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 7
- States / cities
- Denver, Colorado • Washington D.C., District of Columbia • Manhattan, New York + 3 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- vosaroxin + cytarabine, placebo + cytarabine
- Drug
- Lead sponsor
- Sunesis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 711 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 38
- States / cities
- La Jolla, California • Los Angeles, California • San Diego, California + 31 more
- Conditions
- Heart Block Complete, Heart Block Second Degree
- Interventions
- Dexamethasone, No Dexamethasone
- Drug · Other
- Lead sponsor
- The Hospital for Sick Children
- Other
- Eligibility
- 16 Years to 50 Years · Female only
- Enrollment
- 350 participants
- Timeline
- 2020 – 2029
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • San Francisco, California • Denver, Colorado + 9 more
- Conditions
- Advanced Melanoma
- Interventions
- Brenetafusp, Nivolumab, Nivolumab + Relatlimab
- Drug
- Lead sponsor
- Immunocore Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 680 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 37
- States / cities
- Tucson, Arizona • La Jolla, California • Los Angeles, California + 30 more
- Conditions
- HIV Infections
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 297 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 30
- States / cities
- San Francisco, California • Denver, Colorado • Wheat Ridge, Colorado + 14 more
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma, Ann Arbor Stage III Lymphoma, Ann Arbor Stage IV Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Gastroesophageal Junction Adenocarcinoma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Invasive Breast Carcinoma, Kidney Carcinoma, Malignant Hepatobiliary Neoplasm, Malignant Solid Neoplasm, Melanoma, Muscle-Invasive Bladder Carcinoma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma, RISS Stage III Plasma Cell Myeloma, Sarcoma, Stage I Bladder Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage I Colorectal Cancer AJCC v6 and v7, Stage I Esophageal Cancer AJCC V7, Stage I Gastric Cancer AJCC V7, Stage I Lung Cancer AJCC v7, Stage I Ovarian Cancer AJCC v6 and v7, Stage I Pancreatic Cancer AJCC v6 and v7, Stage I Prostate Cancer AJCC v7, Stage I Uterine Corpus Cancer AJCC v7, Stage II Bladder Cancer AJCC v6 and v7, Stage II Breast Cancer AJCC v6 and v7, Stage II Colorectal Cancer AJCC v7, Stage II Esophageal Cancer AJCC v7, Stage II Gastric Cancer AJCC v7, Stage II Lung Cancer AJCC v7, Stage II Ovarian Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage II Prostate Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7, Stage III Bladder Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage III Esophageal Cancer AJCC v7, Stage III Gastric Cancer AJCC v7, Stage III Lung Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage III Prostate Cancer AJCC v7, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Bladder Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Colorectal Cancer AJCC v7, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7, Stage IV Lung Cancer AJCC v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IV Prostate Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, Thyroid Gland Carcinoma
- Interventions
- Questionnaire Administration, Biospecimen Collection
- Other · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 2,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 746
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 501 more
- Conditions
- Breast Cancer
- Interventions
- systemic chemotherapy, axillary lymph node dissection, neoadjuvant therapy, sentinel lymph node biopsy, therapeutic conventional surgery, ultrasound imaging
- Drug · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 756 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2023
- U.S. locations
- 324
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 232 more
- Conditions
- Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Interventions
- Pacritinib, Best Available Therapy
- Drug
- Lead sponsor
- CTI BioPharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 311 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 50
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Duarte, California + 42 more
- Conditions
- Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms
- Interventions
- Vatalanib
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 145
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 123 more
- Conditions
- Acute Coronary Syndrome
- Interventions
- Apolipoprotein A-I [human] (apoA-I), Placebo
- Biological · Other
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18,226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 202
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 175 more
- Conditions
- Pancreatic Neoplasm
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Endoscopic Ultrasound, Endoscopic Ultrasound-Guided Fine-Needle Aspiration, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Surgical Procedure
- Procedure · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 770 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2031
- U.S. locations
- 408
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 290 more
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, HER2/Neu Positive, Progesterone Receptor Negative, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IIIC Breast Cancer AJCC v6, Stage IV Breast Cancer AJCC v6 and v7
- Interventions
- Bevacizumab, Ixabepilone, Laboratory Biomarker Analysis, Nab-paclitaxel, Paclitaxel, Questionnaire Administration
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 799 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2017
- U.S. locations
- 703
- States / cities
- Scottsdale, Arizona • Fort Smith, Arkansas • Jonesboro, Arkansas + 472 more
- Conditions
- COVID-19 Infection, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Interventions
- Biospecimen Collection, Data Collection, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 1,877 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 930
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 590 more